{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:07:13Z","timestamp":1789927633011,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Protoc"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41596-018-0105-7","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T15:45:45Z","timestamp":1546616745000},"page":"541-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9660-2625","authenticated-orcid":false,"given":"Lukas D.","family":"Landegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-0765","authenticated-orcid":false,"given":"Jun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Maimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei R.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Roberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3184-6493","authenticated-orcid":false,"given":"Peigen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina M.","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-183X","authenticated-orcid":false,"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"105_CR1","first-page":"603","volume":"84","author":"DG Evans","year":"1992","unstructured":"Evans, D. G. et al. A clinical study of type 2 neurofibromatosis. Q. J. Med. 84, 603\u2013618 (1992).","journal-title":"Q. J. Med."},{"key":"105_CR2","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","volume":"35","author":"SR Plotkin","year":"2014","unstructured":"Plotkin, S. R., Merker, V. L., Muzikansky, A., Barker, F. G. 2nd & Slattery, W. 3rd Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol. Neurotol. 35, e50\u201356 (2014).","journal-title":"Otol. Neurotol."},{"key":"105_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/AUD.0000000000000238","volume":"37","author":"JS West","year":"2016","unstructured":"West, J. S., Low, J. C. & Stankovic, K. M. Revealing hearing loss: a survey of how people verbally disclose their hearing loss. Ear Hear. 37, 194\u2013205 (2016).","journal-title":"Ear Hear."},{"key":"105_CR4","doi-asserted-by":"publisher","first-page":"e0179973","DOI":"10.1371\/journal.pone.0179973","volume":"12","author":"SY Kim","year":"2017","unstructured":"Kim, S. Y. et al. Severe hearing impairment and risk of depression: a national cohort study. PLoS ONE 12, e0179973 (2017).","journal-title":"PLoS ONE"},{"key":"105_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin, S. R. et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 361, 358\u2013367 (2009).","journal-title":"N. Engl. J. Med."},{"key":"105_CR6","doi-asserted-by":"publisher","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","volume":"115","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc. Natl. Acad. Sci. USA 115, E2077\u2013E2084 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"105_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nprot.2009.28","volume":"4","author":"BA Tannous","year":"2009","unstructured":"Tannous, B. A. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4, 582\u2013591 (2009).","journal-title":"Nat. Protoc."},{"key":"105_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1021\/ac202833r","volume":"84","author":"MS Bovenberg","year":"2012","unstructured":"Bovenberg, M. S., Degeling, M. H. & Tannous, B. A. Enhanced Gaussia luciferase blood assay for monitoring of in vivo biological processes. Anal. Chem. 84, 1189\u20131192 (2012).","journal-title":"Anal. Chem."},{"key":"105_CR9","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao, X. et al. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc. Natl. Acad. Sci. USA 112, 14676\u201314681 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"105_CR10","first-page":"e1787","volume":"2010","author":"SJ Guyenet","year":"2010","unstructured":"Guyenet, S. J. et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J. Vis. Exp. 2010, e1787 (2010).","journal-title":"J. Vis. Exp."},{"key":"105_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrc778","volume":"2","author":"RK Jain","year":"2002","unstructured":"Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nat. Rev. Cancer 2, 266\u2013276 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"105_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nrc3235","volume":"12","author":"BJ Vakoc","year":"2012","unstructured":"Vakoc, B. J., Fukumura, D., Jain, R. K. & Bouma, B. E. Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. Nat. Rev. Cancer 12, 363\u2013368 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"105_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/89997","volume":"7","author":"EB Brown","year":"2001","unstructured":"Brown, E. B. et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat. Med. 7, 864\u2013868 (2001).","journal-title":"Nat. Med."},{"key":"105_CR14","doi-asserted-by":"publisher","first-page":"18599","DOI":"10.1038\/srep18599","volume":"5","author":"S Dilwali","year":"2015","unstructured":"Dilwali, S., Landegger, L. D., Soares, V. Y., Deschler, D. G. & Stankovic, K. M. Secreted factors from human vestibular schwannomas can cause cochlear damage. Sci. Rep. 5, 18599 (2015).","journal-title":"Sci. Rep."},{"key":"105_CR15","first-page":"1498","volume":"18","author":"VY Soares","year":"2016","unstructured":"Soares, V. Y. et al. Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells. Neuro Oncol. 18, 1498\u20131507 (2016).","journal-title":"Neuro Oncol."},{"key":"105_CR16","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong, H. K. et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 70, 3483\u20133493 (2010).","journal-title":"Cancer Res."},{"key":"105_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11060-016-2150-9","volume":"129","author":"NX Bonne","year":"2016","unstructured":"Bonne, N. X. et al. An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth. J. Neurooncol. 129, 47\u201356 (2016).","journal-title":"J. Neurooncol."},{"key":"105_CR18","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1097\/MAO.0000000000001766","volume":"39","author":"CT Dinh","year":"2018","unstructured":"Dinh, C. T. et al. A xenograft model of vestibular schwannoma and hearing loss. Otol. Neurotol. 39, e362\u2013e369 (2018).","journal-title":"Otol. Neurotol."},{"key":"105_CR19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1101\/gad.11.10.1253","volume":"11","author":"AI McClatchey","year":"1997","unstructured":"McClatchey, A. I., Saotome, I., Ramesh, V., Gusella, J. F. & Jacks, T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 11, 1253\u20131265 (1997).","journal-title":"Genes Dev."},{"key":"105_CR20","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1101\/gad.13.8.978","volume":"13","author":"M Giovannini","year":"1999","unstructured":"Giovannini, M. et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 13, 978\u2013986 (1999).","journal-title":"Genes Dev."},{"key":"105_CR21","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","volume":"14","author":"M Giovannini","year":"2000","unstructured":"Giovannini, M. et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14, 1617\u20131630 (2000).","journal-title":"Genes Dev."},{"key":"105_CR22","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1101\/gad.226302","volume":"16","author":"M Kalamarides","year":"2002","unstructured":"Kalamarides, M. et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 16, 1060\u20131065 (2002).","journal-title":"Genes Dev."},{"key":"105_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddu414","volume":"24","author":"JR Gehlhausen","year":"2015","unstructured":"Gehlhausen, J. R. et al. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Hum. Mol. Genet. 24, 1\u20138 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"105_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0896-6273(92)90279-M","volume":"8","author":"A Messing","year":"1992","unstructured":"Messing, A. et al. P0 promoter directs expression of reporter and toxin genes to Schwann cells of transgenic mice. Neuron 8, 507\u2013520 (1992).","journal-title":"Neuron"},{"key":"105_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.neo.7900249","volume":"4","author":"DH Gutmann","year":"2002","unstructured":"Gutmann, D. H. & Giovannini, M. Mouse models of neurofibromatosis 1 and 2. Neoplasia 4, 279\u2013290 (2002).","journal-title":"Neoplasia"},{"key":"105_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1101\/gad.12.8.1121","volume":"12","author":"AI McClatchey","year":"1998","unstructured":"McClatchey, A. I. et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12, 1121\u20131133 (1998).","journal-title":"Genes Dev."},{"key":"105_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1097\/MLG.0b013e31804b1ae7","volume":"117","author":"BA Neff","year":"2007","unstructured":"Neff, B. A. et al. Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope 117, 1069\u20131072 (2007).","journal-title":"Laryngoscope"},{"key":"105_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-1-4939-3801-8_6","volume":"1458","author":"EF Meijer","year":"2016","unstructured":"Meijer, E. F., Baish, J. W., Padera, T. P. & Fukumura, D. Measuring vascular permeability in vivo. Methods Mol. Biol. 1458, 71\u201385 (2016).","journal-title":"Methods Mol. Biol."},{"key":"105_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.neuroimage.2008.12.022","volume":"45","author":"CM McCann","year":"2009","unstructured":"McCann, C. M. et al. Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy. Neuroimage 45, 360\u2013369 (2009).","journal-title":"Neuroimage"}],"container-title":["Nature Protocols"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41596-018-0105-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41596-018-0105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41596-018-0105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:28:08Z","timestamp":1684621688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41596-018-0105-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1038\/s41596-018-0105-7","relation":{},"ISSN":["1754-2189","1750-2799"],"issn-type":[{"value":"1754-2189","type":"print"},{"value":"1750-2799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"7 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.K.J. has received consultant fees from Merck, Ophthotech, Pfizer, Sun Pharma Advanced Research Corporation (SPARC), SynDevRx, and XTuit; owns equity in Enlight, Ophthotech, SynDevRx, and XTuit; serves on the board of directors of XTuit and the boards of trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund; and received honorarium for speaking at AMGEN. No funding or reagents from these companies were used in these studies. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}